Brown-Frandsen K, et al. – In this study, researchers compared the risk of major adverse cardiovascular events (MACE) and mortality between liraglutide vs no liraglutide use in the Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE). Patients with type 2 diabetes and high cardiovascular risk were randomized in a 1:1 ratio to receive either degludec or glargine 100 units/mL (glargine U100). Investigators found that liraglutide treatment in diabetic patients with high cardiovascular risk using basal insulin was related to a significantly lower risk of MACE and death. No significant difference was found in the rate of severe hypoglycemia with vs without liraglutide use.